Generics Bulletin is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Glenmark Pharmaceuticals Limited

http://www.glenmarkpharma.com

Latest From Glenmark Pharmaceuticals Limited

Transformative Innovation: How India Can Up Its Game, Big Pharma GCCs Add Value

A new report discusses the priorities that India should focus on to leapfrog towards transformative innovation. Big pharma’s expanding global capability centres (GCCs) in India are also contributing to the innovation ecosystem while positioning the country as the global industry's “backbone”.

Research & Development Innovation

Glenmark Seeks To Revive US Momentum After Earnings 'Aberration'

Glenmark hopes complex and respiratory products including a potential filing for generic Flovent pMDI can restore some lost sheen of its US business going forward, but a compliance comeback for its Monroe site may be pivotal to deliver material gains.

Strategy Sales & Earnings

Glenmark Seeks To Revive US Momentum After Earnings 'Aberration'

Glenmark hopes complex and respiratory products including a potential filing for generic Flovent pMDI can restore some lost sheen of its US business going forward, but a compliance comeback for its Monroe site may be pivotal to deliver material gains.

Commercial Compliance

US Court Signs Off $70m Glenmark, Merck Settlement In Zetia ‘Pay-For-Delay’ Case

Months after signing off on claims from two other sets of plaintiffs, a US district court in Virginia has approved a settlement agreement with a third class to put to bed antitrust claims that Glenmark and Merck & Co conspired illegally to delay generic competition to Merck’s Zetia blockbuster.

Legal Issues Deals
See All

Company Information

  • Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Drug Delivery
    • Generic Drugs
    • OTC, Consumer
    • Specialty Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
    • Large Molecule
      • Antibodies
  • Other Names / Subsidiaries
    • Integrace
    • Integrace Private Limited
    • Ichnos Sciences
UsernamePublicRestriction

Register